Abstract

Backgound: Patients with severe or uncontrolled asthma may require treatment with oral corticosteroids (OCS) but the harms profile must be carefully considered.Aim: To evaluate risks of morbidity and mortality associated with OCS use in a nationwide Danish asthma cohortMethods: Users of anti-asthmatic drugs (aged 18-45) during 1999-2018 were identified in national healthcare registers. Incident OCS users were matched 1:4 to non-users by propensity scores with replacement. Associations to incident comorbidities (osteoporosis, fractures, osteonecrosis, diabetes type 2, adrenal insufficiency, ischemic heart disease, heart failure, depression/anxiety, peptic ulcer disease, and cataract) were examined by Cox regression. All-cause mortality was estimated by Kaplan-Meier plots.Results: All comorbidities occurred more frequently among OCS-users (n 30,343) with an 1.43 (hazard ratio (HR), 95% CI 1.38-1.48) times increased risk compared to non-users (n 121,372). Adrenal insufficiency and heart failure had the highest HRs of 6.49 (95% CI 3.35-12.59) and 4.49 (95% CI 3.75-5.37), respectively. The most frequent outcomes were depression/anxiety (9,202 cases, HR 1.44, 95% CI 1.38-1.51) followed by fractures and diabetes. OCS-users had higher all-cause mortality than non-users (HR 2.14, 95% 1.94-2.37). The most common causes of death were chronic lower respiratory diseases (19%), mental and behavioural disorders (9%), and ischemic and pulmonary heart diseases (7%).Conclusion: OCS use for asthma is associated with increased risks of comorbidities and mortality, emphasising the importance of high awareness towards this patient group and the necessity of OCS-sparing strategies and management of comorbidities.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 102.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
OriginalsprogEngelsk
Artikelnummer102
TidsskriftEuropean Respiratory Journal
Vol/bind60
Udgave nummersuppl. 66
DOI
StatusUdgivet - 4. sep. 2022
BegivenhedERS International Congress 2022 - Barcelona, Spanien
Varighed: 4. sep. 20226. sep. 2022

Konference

KonferenceERS International Congress 2022
Land/OmrådeSpanien
ByBarcelona
Periode04/09/202206/09/2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Oral corticosteroid-related morbidity and mortality in asthma - a Danish nationwide cohort study'. Sammen danner de et unikt fingeraftryk.

Citationsformater